Targeting Epilepsy Ictogenesis Process Through Pannexin-1 Modulation

Epilepsy, affecting about 1% of the population, comprises a group of neurological disorders characterized by the periodic occurrence of seizures, which disrupt normal brain function. Despite treatment with current antiepileptic drugs, one third of epileptic patients are pharmacoresistant and most patients suffer from side effects, making it crucial to develop novel therapies. Current drugs indeed target channels and receptors involved in normal brain function, not specific to the disease.Our academic work has recently identified a novel and innovative target for epilepsy. Our project thus aims at bringing to the market a new generation of antiepileptic drugs specifically targeting the disease.